Related Experiment Videos
Asthma therapy in the new millennium.
1Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University of Erlangen, Germany. pahl@pharmakologie.uni-erlangen.de
Summary
New therapies for bronchial asthma are emerging, targeting specific pathways like IgE and cytokines. Research explores novel compounds, phosphodiesterase inhibitors, and improved glucocorticoids to manage this growing respiratory disease.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Bronchial asthma is a prevalent chronic respiratory disease with increasing incidence globally.
- Despite effective treatments, understanding of asthma pathogenesis has advanced significantly.
- This progress reveals potential for targeted and novel therapeutic strategies.
Purpose of the Study:
- To review current and emerging therapeutic approaches for bronchial asthma.
- To highlight advancements in understanding asthma pathogenesis and drug development.
- To discuss future directions in asthma management.
Main Methods:
- Review of current literature on asthma pathogenesis and treatment.
- Analysis of investigational therapies including monoclonal antibodies, cytokine inhibitors, and novel receptor antagonists.
- Exploration of new drug classes like phosphodiesterase (PDE) inhibitors and retrometabolic glucocorticoids.
Main Results:
- Monoclonal antibodies targeting IgE, IL-4, and IL-5 are under investigation.
- Development of new compounds targeting novel receptors and cytosolic pathways is ongoing.
- Selective PDE inhibitors show promise, and improved glucocorticoids with fewer side effects are being designed.
Conclusions:
- Future asthma management will benefit from a wider array of targeted therapies.
- Strategies targeting airway remodeling and novel drug delivery systems may play a role.
- Continued research is essential for diverse and effective asthma treatment options.